Last reviewed · How we verify
Ketoprofen and Omeprazole
Ketoprofen inhibits prostaglandin synthesis via COX inhibition to reduce inflammation and pain, while omeprazole suppresses gastric acid production to protect against NSAID-induced ulcers.
Ketoprofen inhibits prostaglandin synthesis via COX inhibition to reduce inflammation and pain, while omeprazole suppresses gastric acid production to protect against NSAID-induced ulcers. Used for Rheumatoid arthritis with gastric protection, Osteoarthritis with gastric protection, Chronic pain conditions requiring NSAID therapy with reduced GI risk.
At a glance
| Generic name | Ketoprofen and Omeprazole |
|---|---|
| Also known as | Lower third molar surgery with Ketoprofen and Omeprazole |
| Sponsor | Luis Fernando Simoneti |
| Drug class | NSAID + Proton pump inhibitor combination |
| Target | COX-1/COX-2 (ketoprofen); H+/K+-ATPase (omeprazole) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
This is a fixed-dose combination pairing an NSAID (ketoprofen) with a proton pump inhibitor (omeprazole). Ketoprofen blocks cyclooxygenase enzymes to reduce prostaglandin-mediated inflammation, pain, and fever. Omeprazole reduces gastric acid secretion by inhibiting the H+/K+-ATPase pump, thereby mitigating the gastrointestinal toxicity risk inherent to chronic NSAID use.
Approved indications
- Rheumatoid arthritis with gastric protection
- Osteoarthritis with gastric protection
- Chronic pain conditions requiring NSAID therapy with reduced GI risk
Common side effects
- Dyspepsia
- Abdominal pain
- Nausea
- Headache
- Dizziness
Key clinical trials
- LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (PHASE1)
- Comparison of the Clinical Efficacy of Ketoprofen, Associated or Not With Omeprazole in Lower Third Molar Removal (PHASE4)
- Safety, Tolerability and Efficacy Study With a Fixed-Dose Combination (FDC) Ketoprofen Plus Omeprazole (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketoprofen and Omeprazole CI brief — competitive landscape report
- Ketoprofen and Omeprazole updates RSS · CI watch RSS
- Luis Fernando Simoneti portfolio CI